Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

Stopped 1. Interim results suggested a reduction of sample size. 2. Anticipated length of enrolment period with resulting funding issues to pose a threat to the study.

Conditions

• Pulmonary Embolism

Interventions

• DRUG: Dabigatran

Sponsor

Prof. Stavros Konstantinides, MD

Collaborators

• [object Object]